Search

Corcept Therapeutics Inc

Gesloten

SectorGezondheidszorg

109.34 -2.43

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

108.84

Max

112.91

Belangrijke statistieken

By Trading Economics

Inkomsten

-130M

-32M

Verkoop

-37M

165M

K/W

Sectorgemiddelde

260.343

64.641

EPS

-0.3

Winstmarge

-19.26

Werknemers

730

EBITDA

-55M

-44M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+8.69% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

4.8B

9.8B

Vorige openingsprijs

111.77

Vorige sluitingsprijs

109.34

Corcept Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

3 aug 2026, 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

31 jul 2026, 22:26 UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

30 jul 2026, 23:11 UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

29 jul 2026, 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

28 jul 2026, 19:46 UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

27 jul 2026, 23:46 UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

24 jul 2026, 21:01 UTC

Corcept Therapeutics shares are lower in after-market trading, reflecting broader negative sentiment following earnings reports from major companies like Tesla and Alphabet.

22 jul 2026, 19:51 UTC

Corcept Therapeutics Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

21 jul 2026, 17:06 UTC

Corcept Therapeutics Inc is trading higher today, reflecting broader market trends as regional indices like the Nikkei 225 also show gains.

20 jul 2026, 18:13 UTC

Social Media

Corcept Therapeutics shares are higher today, boosted by FDA approval of Lifyorli and increased trading volume amid heightened investor interest.

Peer Vergelijking

Prijswijziging

Corcept Therapeutics Inc Prognose

Koersdoel

By TipRanks

8.69% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 122.6 USD  8.69%

Hoogste 165 USD

Laagste 50 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corcept Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

4

Buy

0

Hold

1

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat